玻璃体内注射康柏西普治疗特发性脉络膜新生血管  

Effect of intravitreal Conbercept for idiopathic choroidal neovascularization

作　　者：翟改霞 王少鹏[1] 苏元镇 王作芬[1] 信兆亭 ZHAI Gaixia;WANG Shaopeng;SU Yuanzhen;WANG Zuofen;XIN Zhaoting(Department of Ophthalmology,Zibo Central Hospital,Zibo 255000,Shandong Province,China;Department of Cardiology,Zibo Central Hospital,Zibo 255000,Shandong Province,China)

机构地区：[1]淄博市中心医院眼科,山东省淄博市255000 [2]淄博市中心医院心内科,山东省淄博市255000

出　　处：《眼科新进展》2020年第1期66-69,共4页Recent Advances in Ophthalmology

摘　　要：目的观察玻璃体内注射康柏西普治疗特发性脉络膜新生血管(idiopathic choroidal neovascularization,ICNV)的临床疗效。方法对2015年6月至2017年10月于我院确诊并行玻璃体内注射0.05 mL(0.5 mg)康柏西普治疗的20例20眼ICNV患者的临床资料进行回顾性分析,所有患者均采用1+PRN治疗策略,第1次随访时间为首次注射后1周,以后每月随访1次,均完成6个月的随访。记录CNV病灶渗漏情况、最佳矫正视力(best corrected visual acuity,BCVA)、黄斑中心凹视网膜厚度(central macular retinal thickness,CRT)、眼部及全身不良反应等。结果20眼中,玻璃体内注射1~3(1.60±0.68)次,其中注射1次者10眼,注射2次者8眼,注射3次者2眼。治疗前BCVA为(55.15±6.82)个字母数,治疗后1周、1个月、3个月、6个月分别为(61.50±6.16)个字母数、(71.00±5.10)个字母数、(73.90±6.75)个字母数、(77.95±5.12)个字母数,治疗前患者CRT为(342.75±36.39)μm,治疗后1周、1个月、3个月、6个月分别为(301.15±32.16)μm、(231.85±30.25)μm、(240.05±56.99)μm、(229.75±48.18)μm,治疗后各时间点BCVA及CRT与治疗前相比差异均有统计学意义(均为P<0.05)。随访6个月时,17眼病灶渗漏停止,3眼病灶渗漏面积明显缩小,20眼均未出现新的病灶。所有患眼在随访期间均未发生青光眼、眼内炎、白内障进展、视网膜脱离等眼部严重并发症或全身不良反应。结论玻璃体内注射康柏西普治疗ICNV安全有效。Objective To observe the clinical efficacy of intravitreal Conbercept in the treatment of idiopathic choroidal neovascularization(ICNV).Methods Retrospective analysis was conducted on clinical data of 20 patients(20 eyes)who were diagnosed with ICNV and received intravitreal injection of 0.05 mL(0.5 mg)Conbercept from June 2015 to October 2017 in our hospital.All patients received 1+PRN treatment strategy.The first follow-up was taken 1 week after the first injection,followed by follow-up monthly for 6 months.CNV lesion leakage,best-corrected visual acuity(BCVA),central retinal thickness(CRT),ocular and systemic adverse reactions were recorded.Results All the 20 eyes were given intravitreal Conbercept for one to three times(1.60±0.68),including one time in 10 eyes,two times in 8 eyes and three times in 2 eyes.BCVA was(55.15±6.82)letters before treatment,(61.50±6.16)letters,(71.00±5.10)letters,(73.90±6.75)letters and(77.95±5.12)letters at 1 week,1 month,3 months and 6 months follow-up,respectively.CRT was(342.75±36.39)μm before treatment,(301.15±32.16)μm,(231.85±30.25)μm,(240.05±56.99)μm and(229.75±48.18)μm at 1 week,1 month,3 months and 6 months follow-up.Statistical differences were found in BCVA and CRT at each time points after treatment comparing with that before treatment respetively(all P<0.05).At 6 months follow-up,fluorescein leakage disappeared in 17 eyes,fluorescein leakage area decreased in 3 eyes and no new lesions were found in 20 eyes.During the follow-up,no serious ocular or systemic adverse reactions including glaucoma,intraocular infection,cataract progression,retinal detachment occurred in all 20 eyes.Conclusion Intravitreal Conbercept is a safe and effective treatment for ICNV.

关 键 词：康柏西普 特发性脉络膜新生血管 血管内皮生长因子 

分 类 号：R773.4[医药卫生—眼科]